{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["28(4)"],"submitter":["Dulovic A"],"pubmed_abstract":["Patients undergoing chronic hemodialysis were among the first to receive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations because of their increased risk for severe coronavirus disease and high case-fatality rates. By using a previously reported cohort from Germany of at-risk hemodialysis patients and healthy donors, where antibody responses were examined 3 weeks after the second vaccination, we assessed systemic cellular and humoral immune responses in serum and saliva 4 months after vaccination with the Pfizer-BioNTech BNT162b2 vaccine using an interferon-γ release assay and multiplex-based IgG measurements. We further compared neutralization capacity of vaccination-induced IgG against 4 SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, and Delta) by angiotensi"],"journal":["Emerging infectious diseases"],"pagination":["743-750"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8962909"],"repository":["biostudies-literature"],"pubmed_title":["Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination."],"pmcid":["PMC8962909"],"pubmed_authors":["Junker D","Cossmann A","Becker M","Beigel A","Ramos GM","Kaiser PD","Dulovic A","Griesbaum J","Dopfer-Jablonka A","Behrens GMN","Strengert M","Lurken K","Wrenger E","Rothbauer U","Lonnemann G","Stankov MV","Traenkle B","Krause G","Schneiderhan-Marra N"],"additional_accession":[]},"is_claimable":false,"name":"Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination.","description":"Patients undergoing chronic hemodialysis were among the first to receive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations because of their increased risk for severe coronavirus disease and high case-fatality rates. By using a previously reported cohort from Germany of at-risk hemodialysis patients and healthy donors, where antibody responses were examined 3 weeks after the second vaccination, we assessed systemic cellular and humoral immune responses in serum and saliva 4 months after vaccination with the Pfizer-BioNTech BNT162b2 vaccine using an interferon-γ release assay and multiplex-based IgG measurements. We further compared neutralization capacity of vaccination-induced IgG against 4 SARS-CoV-2 variants of concern (Alpha, Beta, Gamma, and Delta) by angiotensi","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-19T20:12:56.769Z","creation":"2025-04-19T20:12:56.769Z"},"accession":"S-EPMC8962909","cross_references":{"pubmed":["35203113"],"doi":["10.3201/eid2804.211907"]}}